Luma Vision Ltd. raised $22 million in financing that will allow the company to secure U.S. FDA approval and prepare for commercialization of its 4D cardiac imaging technology platform, Verafeye. The series A3 financing round was led by existing investors EQT Lifesciences, ABV Uni Fund and imec.xpand. Luma also added three new investors comprising an undisclosed multinational strategic investor, Atlantic Bridge Growth Fund and Bayern Kapital.
Robocath SAS said it performed the world’s first-in-human remote robotic coronary angioplasty between two cities in China, Beijing and Urumqi, located 1,700 miles apart. The procedure was carried out using the company’s R-One robotic platform, via a 5G connection, and paves the way for long-distance endovascular procedures.
To date, no cardiovascular model has been able to shed light on how and why cardiac congenital disorders start in the human embryo. Researchers from the Institute of Molecular Biotechnology (IMBA) in Vienna have been able to recapitulate cardiogenesis in multi-chamber cardioids, sort of interacting heart chambers intended to dissect how genetic and environmental factors impact human heart development.
Backbeat Medical Inc. is seeking patent protection for methods and systems for controlling blood pressure to either treat hypertension by using a first electrical stimulation pattern that reduces both systolic blood pressure and diastolic blood pressure.
Kaneka Corp. has acquired Japan Medical Device Technology Co. Ltd. (JMDT), to expand its reach in the coronary stent business segment. Financial terms of the deal were not disclosed.
Edwards Lifesciences Corp. set analysts a-spin ahead of its investor day activities with the revelation it plans to launch its critical care unit as a stand-alone public company next year. Edwards expects that dividing the business will allow it to focus on cardiovascular and surgical markets.
Omini SA hopes that the multiplexed blood testing platform it is developing will transform the lives of patients suffering from heart failure. With its multiplex, sensor-based testing strip that simultaneously measures four key biomarkers from a single drop of blood, the company’s technology should increase the chance of a patient’s survival and reduce pressure on health care systems, Joanne Kanaan, CEO and co-founder of Omini, told BioWorld.
A Genentech Inc. patent discloses new benzothiazole compounds acting as von Hippel-Lindau disease tumor suppressor (VHL) inhibitors and reported to be useful for the treatment of ischemia, cancer and anemia.
Johnson & Johnson completed the previously unheralded acquisition of privately held Laminar Inc. for $400 million upfront, with undisclosed contingent payments depending on achievement of clinical and regulatory milestones starting in 2024. The deal provides the med-tech giant a potentially game-changing entree into the lucrative left atrial appendage (LAA) market.
RSS
